№ files_lp_4_process_3_067782
File format: docx
Character count: 13557
File size: 1559 KB
Consent form for a medical research study outlining participation requirements, procedures, risks, alternatives, and data handling for patients receiving cord blood transplants under an access protocol for units not yet FDA-approved.
Year:
2011
Region / City:
United States
Subject Area:
Medical research, hematology, transplantation
Document Type:
Informed consent form
Organization / Institution:
National Marrow Donor Program (NMDP), Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin
Principal Investigator:
<< Enter name/title of Principal Investigator>>
Sponsors / Funding:
NMDP/Be The Match, CIBMTR
Target Audience:
Patients undergoing cord blood transplant and their legal guardians
Study Period:
One year post-transplant
Date of Initiation:
October 2011
Procedures:
Cord blood infusion, medical data collection, post-transplant follow-up
Risks:
Infusion-related complications, infection risk, slow blood count recovery, potential unknown side effects
Alternatives:
Use of licensed cord blood units, transplant from unrelated donor, symptom-control treatment
Data Privacy:
Patient data labeled with number code, monitored for unauthorized access
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document Type:
Supplemental table
Topic:
Anti-SARS-CoV-2 spike protein IgG seroconversion
Subject:
Hematologic malignancies and healthy controls
Medical Context:
COVID-19 vaccination response
Vaccines Included:
BNT162b2; mRNA1273; Ad26.COV2.S; ChyAdOx1
Antibody Test Platforms:
Elecsys; AdviseDx Abbott; Liaison; DBS; Sero-Klir Kantaro; Beckman Coulter; Sino Biological; Meso Scale Discovery; Platelia
Countries Represented:
United States; United Kingdom; Israel; Denmark; Italy
Patient Groups:
ALL/AML; CLL; CML/MPD; MDS; WM; MM; NHL; Healthy controls
Sample Size Range per Study:
21–650 participants
Combined Healthy Control Sample Size:
729
Primary Outcome Measure:
Seroconversion rate after full vaccination
Source Basis:
Published and in-press peer-reviewed studies
Year:
2017
Region / City:
N/A
Topic:
Hematologic Toxicities, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Document Type:
Meta-analysis
Organization:
N/A
Author:
N/A
Target Audience:
Researchers, Healthcare Professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
2/2018
Year:
2022
Region / city:
Glasgow, United Kingdom
Topic:
Gynaecological oncology, surgery
Document type:
Research article
Organization / institution:
Glasgow Royal Infirmary
Author:
Mr. Chia Yew Kong, Mr. Norman Galbraith, Mr. John Telfer, Prof Steven Lo, Mr. Neil Fairbairn, Mr. Michael Palmer, Mr. Seamus Teahan, Dr. Rhona Lindsay, Dr. Kevin Burton, Professor Campbell Roxburgh, Mr. Peter Chong, Mr. Colin Steele, Dr. Aiste McCormick, Miss Martha Quinn
Target audience:
Medical professionals, researchers in oncology
Period of action:
2018-2022
Approval date:
Not specified
Modification date:
Not specified
Document Type:
Supplemental scientific table
Subject:
Peritoneal mesothelioma and genitourinary malignancies
Study Types Included:
Population-based studies, retrospective studies, case reports, case series
Data Sources Mentioned:
SEER database
Malignancies Covered:
Cervical cancer, endometrial adenocarcinoma, ovarian carcinoma, renal cell carcinoma, prostate cancer, bladder cancer, testicular seminoma, small cell prostatic cancer
Exposure Variable:
Asbestos exposure
Reported Outcomes:
Synchronous and metachronous malignancies, prior primary cancers, incidence rate ratios
Patient Population:
Individuals diagnosed with peritoneal mesothelioma
Abbreviations:
GU, PM, SEER, RCC, WDPM, GIST
Document Type:
Supplemental table
Topic:
Anti-SARS-CoV-2 spike protein IgG seroconversion
Subject:
Hematologic malignancies and healthy controls
Medical Context:
COVID-19 vaccination response
Vaccines Included:
BNT162b2; mRNA1273; Ad26.COV2.S; ChyAdOx1
Antibody Test Platforms:
Elecsys; AdviseDx Abbott; Liaison; DBS; Sero-Klir Kantaro; Beckman Coulter; Sino Biological; Meso Scale Discovery; Platelia
Countries Represented:
United States; United Kingdom; Israel; Denmark; Italy
Patient Groups:
ALL/AML; CLL; CML/MPD; MDS; WM; MM; NHL; Healthy controls
Sample Size Range per Study:
21–650 participants
Combined Healthy Control Sample Size:
729
Primary Outcome Measure:
Seroconversion rate after full vaccination
Source Basis:
Published and in-press peer-reviewed studies
Year:
2023
Region / City:
Wisconsin
Subject:
Child Placement
Document Type:
Form
Agency / Institution:
Wisconsin Department of Children and Families
Author:
Wisconsin Department of Children and Families
Target Audience:
Social Workers, Case Managers
Effective Period:
Indefinite
Approval Date:
2023
Amendment Date:
Not specified
Year:
Not specified
Region / City:
Not specified
Theme:
Nursing Care, Assisted Living
Document Type:
Policy
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Licensed Nurses, Unlicensed Assistive Personnel, Healthcare Providers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Program:
BEAD
Document Type:
Evidence Template Instructions and Schema
Purpose:
Guidance for completing the Unlicensed Fixed Wireless Service Evidence Template
Applicable Policy:
NTIA BEAD Restructuring Policy Notice
Issue Date:
June 6, 2025
Target Audience:
BEAD applicants
Submission Requirements:
All fields in Tabs 2–8 must be completed with supplemental evidence files
Content:
Network design assumptions, tower sites, sectors, BSLs, uplink/downlink MCS tables, logical network diagram
Technology Focus:
Unlicensed Fixed Wireless (ULFW)
Network Specifications:
Throughput, latency, coverage, oversubscription, RAN configurations, interference mitigation, system redundancy
Version number:
5.0
Date ratified:
July 2024
Implementation Date:
July 2024
Last Review Date:
July 2024
Next Review date:
July 2027
Approved by (Sponsor Group):
Medicines Committee
Ratified by:
Medicines Committee
Consultation Groups:
Medicines Committee; Community Health Service Policy Alignment Group
Name of originator/author:
Lead Pharmacist Tower Hamlets Community Health Service; Medicines Safety Officer
Executive Director lead:
Chief Medical Officer
Applicable services:
Trust wide
Related organisation:
East London NHS Foundation Trust
Regulatory authority referenced:
Medicines and Healthcare products Regulatory Agency
Subject:
Prescribing, supply and administration of unlicensed and off-label medicines
Scope:
All staff involved in prescribing and administration of unlicensed and off-label medicines
Review cycle:
Three years
Year:
2026
Region / city:
Washington
Topic:
Wireless Communication, IoT, AR/VR
Document Type:
Order
Organization / Institution:
Federal Communications Commission
Author:
Federal Communications Commission
Target Audience:
Industry professionals, consumers, wireless and IoT technology developers
Period of Action:
January 29, 2026
Approval Date:
January 29, 2026
Amendment Date:
N/A
Year:
2005
Region / City:
United Kingdom
Subject:
Gambling, Licensing
Document Type:
Application form, Official letter
Authority:
Gambling Commission
Author:
Licensing Authority
Target Audience:
Operators of family entertainment centres
Validity Period:
10 years
Approval Date:
N/A
Amendment Date:
N/A
Year:
2018
Date:
July 12, 2018
Region:
Brooklyn, New York, United States
Issuing Authority:
Federal Communications Commission, Enforcement Bureau, Region One, Columbia Regional Office
Case Number:
EB-FIELDNER-17-00023832
Addressee:
Rockaway154 LLC
Subject:
Unlicensed FM radio operation on 93.7 MHz
Legal Basis:
Section 301 of the Communications Act of 1934, as amended
Related Regulations:
Part 15 of the Commission’s Rules
Investigating Office:
New York Office, Enforcement Bureau
Investigating Date:
April 27, 2018
Signatory:
David C. Dombrowski, Regional Director, Region One
Attachments:
Excerpts from the Communications Act of 1934, As Amended; Enforcement Bureau “Inspection Fact Sheet”, March 2005
Year:
2018
Date:
September 19, 2018
Case Number:
EB-FIELDSCR-18-00026287
Issuing Authority:
Federal Communications Commission, Enforcement Bureau, Region Two, Atlanta Regional Office
Regional Director:
Ronald D. Ramage
Recipient:
Marques Dumerant
Location Investigated:
Delray Beach, Florida
Frequencies Involved:
91.7 MHz and 95.1 MHz
Legal Basis:
Section 301 of the Communications Act of 1934, as amended
Type of Document:
Enforcement Notice
Subject:
Unlicensed FM Radio Operation
Response Deadline:
Ten (10) days from date of notice
Attachments:
Excerpts from the Communications Act of 1934, As Amended; Enforcement Bureau "Inspection Fact Sheet," March 2005
Year:
2026
Region / City:
Stafford, UK
Subject:
Gambling / Licensing
Document Type:
Application Form
Issuing Authority:
Stafford Borough Council
Applicable Legislation:
Gambling Act 2005, Gaming Act 1968
Permit Type:
Unlicensed Family Entertainment Centre Gaming Machine Permit
Fee:
£300 for new grant, £100 for conversion, £25 for name change
Duration of Permit:
10 years
Eligibility:
Applicants 18 years or older
Submission Requirements:
Completed form, existing Section 34 permit (if applicable), applicable fee
Year:
1998
Region / City:
United States
Subject:
Deliberate misconduct by unlicensed individuals
Document Type:
Federal Register Notice
Organization / Institution:
U.S. Nuclear Regulatory Commission (NRC)
Author:
U.S. Nuclear Regulatory Commission
Target Audience:
Licensees, applicants, contractors, and subcontractors within the nuclear industry
Period of Action:
From 2/12/98
Approval Date:
2/12/98
Date of Modifications:
Not specified
Year:
2023
Location:
Xiamen, China
Subject:
5G NR sidelink carrier aggregation and unlicensed spectrum operation
Document type:
Technical contribution / meeting report
Organization:
3GPP TSG-RAN WG4
Author:
Huawei, HiSilicon
Agenda item:
5.30.2.1.2
Meeting number:
108bis
Target audience:
3GPP working group participants
Period:
October 09 – October 13, 2023
Related specifications:
NR Rel-16, Rel-17, Rel-18, TR38.886
Frequency bands:
FR1 licensed, n46, n47
Technical focus:
MPR evaluation, PSFCH resource allocation, carrier aggregation mechanism
Simulation parameters:
bandwidth, numerology, modulation, waveform, resource allocation, power calibration
Use cases:
V2X sidelink communications
Year:
2021
Organization:
3GPP TSG-RAN
Meeting:
WG1 Meeting #105-e
Document type:
Meeting Report / Technical Summary
Source:
Moderator (Ericsson)
Agenda item:
8.3.2
Target audience:
RAN1 members, telecom engineers
Discussion period:
May 10 – 27, 2021
Topics:
NR-U, URLLC, CG harmonization, HARQ processes, RRC parameters
Decisions:
Options for enabling/disabling CG-UCI and CG-DFI procedures for unlicensed bands
Observations:
Comparison of configuration options and company preferences